Literature DB >> 24720741

Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial.

T Heise1, L Nosek, S Dellweg, E Zijlstra, K A Præstmark, J Kildegaard, G Nielsen, T Sparre.   

Abstract

AIM: The aim of this study was to assess pain associated with subcutaneous injection into the abdomen and thigh of different combinations of injection speeds and volumes.
METHODS: The study was a single-centre, one-visit, double-blinded, randomized controlled trial in 82 adults with type 1 or type 2 diabetes receiving daily injections of insulin or glucagon-like peptide-1 (GLP-1) agonists. Participants received 17 subcutaneous injections (12 in abdomen, 5 in thigh) of saline at different injection speeds (150, 300 and 450 µl/s), with different volumes (400, 800, 1200 and 1600 µl), and two needle insertions without any injection. Pain was evaluated on a 100-mm visual analogue scale (VAS) (0 mm no pain, 100 mm worst pain) and on a yes/no scale for pain acceptability.
RESULTS: Injection speed had no impact on injection pain (p = 0.833). Injection of larger volumes caused significantly more pain [VAS least square mean differences 1600 vs. 400 µl, 7 · 2 mm (95% confidence interval - CI; 4.6-9.7; p < 0.0001); 1600 vs. 800 µl, 7.2 mm (4.4-10.0; p < 0.0001); 1200 vs. 400 µl, 3.5 mm (0.4-6.6; p = 0.025) and 1200 vs. 800 µl, 3.6 mm (0.4-6.7; p = 0.027)]. Significantly more pain occurred in the thigh versus the abdomen [9.0 mm (6.7-11.3; p < 0.0001)].
CONCLUSIONS: Injection speed had no effect on injection pain, whereas higher injection volumes caused more pain. The results of this study may be of value for guiding patients to use the appropriate injection site and technique to reduce their injection pain. Furthermore, these findings may have important implications for the development of new injection devices and drug formulations for clinical practice.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  diabetes; injection speed; injection volume; subcutaneous injections

Mesh:

Substances:

Year:  2014        PMID: 24720741     DOI: 10.1111/dom.12304

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  32 in total

1.  Insulin Injection Practice and Injection Complications - Results from the Bangladesh Insulin Injection Technique Survey.

Authors:  Abm Kamrul-Hasan; Ajit Kumar Paul; Mohammad Nurul Amin; Md Abu Jar Gaffar; Md Asaduzzaman; Mohammad Saifuddin; Marufa Mustari; Md Jahangir Alam; Mohammad Moin Shahid; K M Nahid-Ul-Haque; Muhammad Shah Alam; Md Motiur Rahman; Samir Kumar Talukder; Md Abdul Kader; Farhana Akter; Mohammad Abdul Hannan; Palash Kumar Chanda; Muhammed Abu Bakar; Shahjada Selim
Journal:  Eur Endocrinol       Date:  2020-02-28

2.  Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.

Authors:  Glenn Matfin; Kate Van Brunt; Alan G Zimmermann; Rebecca Threlkeld; Debra A Ignaut
Journal:  J Diabetes Sci Technol       Date:  2015-04-21

3.  FlexTouch: An Insulin Pen-Injector with a Low Activation Force Across Different Insulin Formulations, Needle Technologies, and Temperature Conditions.

Authors:  Niels Gudiksen; Thibaud Hofstätter; Birgitte B Rønn; Thomas Sparre
Journal:  Diabetes Technol Ther       Date:  2017-07-13       Impact factor: 6.118

4.  Local infiltration versus laparoscopic-guided transverse abdominis plane block in laparoscopic cholecystectomy: double-blinded randomized control trial.

Authors:  Rohan C Siriwardana; Sumudu K Kumarage; Bhagya M Gunathilake; Suchintha B Thilakarathne; Jeevani S Wijesinghe
Journal:  Surg Endosc       Date:  2018-06-25       Impact factor: 4.584

5.  Injection Technique and Pen Needle Design Affect Leakage From Skin After Subcutaneous Injections.

Authors:  Kezia Ann Præstmark; Bente Stallknecht; Morten Lind Jensen; Thomas Sparre; Nils Berg Madsen; Jonas Kildegaard
Journal:  J Diabetes Sci Technol       Date:  2016-06-28

6.  Impact of Injection Speed, Volume, and Site on Pain Sensation.

Authors:  Eric Zijlstra; Johannes Jahnke; Annelie Fischer; Christoph Kapitza; Thomas Forst
Journal:  J Diabetes Sci Technol       Date:  2017-10-08

Review 7.  Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care.

Authors:  Davide Meani; Mladen Solarić; Harri Visapää; Rose-Marie Rosén; Robert Janknegt; Majana Soče
Journal:  Ther Adv Urol       Date:  2017-11-23

8.  Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.

Authors:  Søren Snitker; Andreas Andersen; Birgitte Berg; Sjoerd van Marle; Thomas Sparre
Journal:  Diabetes Obes Metab       Date:  2021-03-18       Impact factor: 6.577

9.  Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance.

Authors:  Cecile Berteau; Orchidée Filipe-Santos; Tao Wang; Humberto E Rojas; Corinne Granger; Florence Schwarzenbach
Journal:  Med Devices (Auckl)       Date:  2015-11-11

10.  Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial.

Authors:  Samaneh Kabul; Robert C Hood; Ran Duan; Amy M DeLozier; Julie Settles
Journal:  Health Qual Life Outcomes       Date:  2016-09-30       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.